Exponent, Inc. — Form 10-Q Summary
Period: Quarter and six months ended June 30, 2023; comparative periods ended July 1, 2022. The request metadata says 2022 Q2, but the supplied filing is for 2023 Q2.
Business context and financial performance
Exponent provides multidisciplinary engineering and scientific consulting services. Its two reportable segments are Engineering and Other Scientific, and Environmental and Health. Figures below are in millions of dollars unless stated otherwise.
- Q2 revenue: $140.2, up 7.6%; revenue before reimbursements was $129.7, up 9.7%.
- Q2 profitability: Operating income was $29.9, down 34.0%, and net income was $25.7, essentially unchanged. Diluted EPS rose to $0.50 from $0.49. Operating margin on total revenue was 21.3%, versus 34.8% a year earlier; net margin was 18.4%, versus 19.8%.
- First-half revenue and earnings: Revenue was $280.5, up 8.4%; revenue before reimbursements was $258.4, up 9.4%. Operating income was $59.0, down 28.0%, while net income was $54.9, down 0.9%. Diluted EPS was $1.06, versus $1.05.
- Cash flow: First-half operating cash flow was $33.8, compared with $23.8. Capital expenditures were $11.1, versus $5.9, leaving approximate operating cash flow less capital expenditures of $22.7. Cash declined $13.3 to $148.2.
- Liquidity and debt: Current assets were $344.6 and current liabilities $124.5. The filing reports no borrowings or other financial debt; operating lease liabilities totaled $28.8. Management said cash and operating cash generation should cover needs for at least 12 months.
- Other measures: Q2 EBITDA was $36.8, or 28.4% of revenue before reimbursements, versus $37.1 and 31.4%. First-half EBITDA was $72.6, or 28.1%, versus $71.5 and 30.3%. These are non-GAAP measures.
Material changes and management commentary
- Q2 demand for reactive services—including product safety and disputes work—was robust. Proactive demand improved in chemicals and life sciences, partly offset by moderation in electronics. Management also cited continuing demand in transportation and construction.
- Q2 billable hours increased 4% to 388,000, while utilization fell to 69% from 77%. Technical full-time equivalent employees increased 15% to 1,077. Management attributed lower utilization to hiring and comparison with unusually strong prior-year utilization.
- Engineering and Other Scientific revenue rose 6.9% in Q2; Environmental and Health revenue rose 11.6%. First-half segment revenue increased 9.3% and 4.1%, respectively.
- Compensation and related expense rose 41.7% in Q2 and 31.3% for the first half. A substantial portion of the reported increase reflected deferred-compensation plan market movements, with corresponding gains in other income. Excluding that offsetting item, payroll, benefits, hiring and stock compensation also increased.
- Management expects compensation expense excluding deferred-compensation asset-value changes to decrease as resources are aligned with expected demand. It expects other operating and general and administrative expenses to rise with infrastructure, office-return, business development and staff development investments. No numeric earnings or revenue guidance was provided.
- Q2 cash dividends declared were $0.26 per share; the board announced a $0.26-per-share dividend payable September 22, 2023. No shares were repurchased in Q2; $62.6 remained under the announced repurchase authorization.
Risks, contingencies and unusual items
- A client sought a $2.0 concession over project performance. Exponent disputes the request; management said the outcome is uncertain but believes it is unlikely to materially adversely affect the business or financial statements.
- Management identified risks including changes in economic and industry conditions, engagement timing, competition and pricing, lack of backlog, ability to attract and retain employees, regulation and claims. It cautioned that forward-looking statements are uncertain.
- The company has foreign-currency exposure and does not hedge it with foreign exchange contracts. It said prior impacts were not significant, while noting international growth could increase future exposure.
- Deferred compensation plan assets are held in a rabbi trust and remain subject to creditor claims. The plan’s vested liabilities were $110.2 at June 30, 2023.
- No material legal proceedings or material changes to previously disclosed risk factors were reported. Disclosure controls were deemed effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the reporting-period discrepancy: the supplied filing covers Q2 2023, not Q2 2022.
- Assess utilization and hiring trends, and whether added technical capacity converts into billable hours and revenue without further margin pressure.
- Separate deferred-compensation market effects, which substantially offset between compensation expense and other income, from underlying operating trends.
- Monitor the $2.0 million client concession dispute, receivables and collections, and the impact of higher capital spending and lease commitments.
- Review cash returns and capital allocation, including the dividend, unused repurchase authorization and management’s stated potential use of cash for acquisitions.